Harbour BioMed to Present Results from P-Ib Study of Porustobart + Toripalimab in Patients with Hepatocellular Carcinoma at ASCO 2023
Shots:
- This is a P-Ib dose-expansion study, evaluating the safety, tolerability, PK/PD, and preliminary efficacy of porustobart/HBM4003 (0.45 mg/kg) + toripalimab (240 mg Q3W) in patients (n=28) with advanced HCC and other solid tumors
- Patients (n=16) who failed previous anti-VEGFR treatment while have not received anti-PDL1 treatment (Cohort 1) and patients (n=12) who failed previous anti-PD-L1 and anti-VEGFR treatments (Cohort 2)
- As of 9 Dec 2022, the median follow-up time was 3.6mos. while the ORR and DCR of Cohort 1 vs Cohort 2 were 46.7% and 73.3% vs 9.1% and 54.5%. TRAEs were reported in 89.3% (25/28) patients, and Gr3. TRAEs were reported in 39.3% (11/28) patients. No Gr4 or Gr5 TRAE was reported
Ref: PRNewswire | Image: Harbour
Related News:- Harbour BioMed Reports P-III Trial Results of Batoclimab for the Treatment of Generalized Myasthenia Gravis
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
